Data Sheet (Cat.No.T14507)

TargetMol

Bay 60-7550

Chemical Properties



CAS No. : 439083-90-6

Formula: C27H32N4O4

Molecular Weight: 476.57

Storage: Store at low temperature
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Actual storage temperature shall be subject to the COA.

Biological Description

Description	Bay 60-7550 is a selective and potent PDE2 inhibitor (Ki: 3.8 nM) that exerts positive inotropic effects on rat heart by increasing PKA-mediated phosphorylation and can be used to ameliorate cognitive impairments and memory disorders.
Targets(IC50)	PDE
In vitro	The anti-proliferative effect of BAY 60-7550 (1 μM) is pronounced, with a significant decrease in proliferation observed in PASMCs from IPAH patients compared to untreated control cells[2].
In vivo	Administration of the PDE2 inhibitors Bay 60-7550 (0.5, 1, and 3 mg/kg) or ND7001 (1 mg/kg), or the NO donor detanonoate (0.5 mg/kg), antagonized the anxiety-like behavior induced by restraint stress in mice [1].

Solubility Information

Solubility	DMSO: 30 mg/mL (62.95 mM),Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)
In vivo Formulation	10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (4.2 mM),Sonication is recommended. *Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.*

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	2.0983 mL	10.4916 mL	20.9833 mL
5 mM	0.4197 mL	2.0983 mL	4.1967 mL
10 mM	0.2098 mL	1.0492 mL	2.0983 mL
50 mM	0.042 mL	0.2098 mL	0.4197 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

Masood A, et al. Anxiolytic effects of phosphodiesterase-2 inhibitors associated with increased cGMP signaling. J Pharmacol Exp Ther. 2009 Nov;331(2):690-9.
Bubb KJ, et al. Inhibition of phosphodiesterase 2 augments cGMP and cAMP signaling to ameliorate pulmonary hypertension. Circulation. 2014 Aug 5;130(6):496-507.